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Missense mutations in the C-terminal B30.2 domain
of pyrin cause familial Mediterranean fever (FMF),
the most common Mendelian autoinflammatory
disease. However, it remains controversial as to
whether FMF is due to the loss of an inhibitor of
inflammation or to the activity of a proinflammatory
molecule. We generated both pyrin-deficient mice
and ‘‘knockin’’ mice harboring mutant human B30.2
domains. Homozygous knockin, but not pyrin-defi-
cient, mice exhibited spontaneous bone marrow-
dependent inflammation similar to but more severe
than human FMF. Caspase-1 was constitutively acti-
vated in knockin macrophages and active IL-1b was
secreted when stimulated with lipopolysaccharide
alone, which is also observed in FMF patients. The
inflammatory phenotype of knockin mice was com-
pletely ablated by crossing with IL-1 receptor-defi-
cient or adaptor molecule ASC-deficient mice, but
not NLRP3-deficient mice. Thus, our data provide
evidence for an ASC-dependent NLRP3-indepen-
dent inflammasome in which gain-of-function pyrin
mutations cause autoinflammatory disease.
INTRODUCTION
Familial Mediterranean fever (FMF;MIM 249100) is the prototype
and the most common of a class of disorders, termedMendelian
autoinflammatory diseases, that are characterized by recurring
spontaneous episodes of fever and localized inflammation
without high-titer autoantibodies or antigen-specific T cells (Ga-
lon et al., 2000; Kastner et al., 2010; Masters et al., 2009). There
is a growing body of data supporting the view that these condi-
tions represent genetic lesions of the innate immune system.
FMF inflammation is mediated by a massive influx of polymor-phonuclear leucocytes into the affected tissues, neutrophilia,
and a rapid acute phase response. The gene responsible for
FMF, designated MEFV, is composed of 10 exons encoding
a 781 amino acid protein known as pyrin (also known as mare-
nostrin) (French FMF Consortium, 1997; The International FMF
Consortium, 1997). So far more than 50 FMF-associated muta-
tions have been identified within MEFV (Touitou et al., 2004).
The carrier frequencies for FMF in the Middle East are as high
as 1:3, suggesting that pyrin mutations may confer a selective
advantage, possibly related to their effects on innate immunity.
Pyrin is expressed predominantly in innate immune cells such
as neutrophils, monocytes, and dendritic cells, but not in lym-
phocytes. In monocytes, the expression is variable and upregu-
lated by proinflammatory cytokines, interferon-g (IFN-g) or tumor
necrosis factor-a (TNF-a) (Centola et al., 2000; Diaz et al., 2004).
Pyrin is composed of at least five domains and each domain has
a distinct role in interactions with several proteins that are related
to inflammation (Chae et al., 2009). The most notable domain of
pyrin is the N-terminal PYRIN domain (also called PYD, PAAD, or
DAPIN). The PYRIN domain is also found in a large number of
proteins implicated in the control of inflammation. PYRIN
domain-containing proteins play a key role in the inflamma-
somes, cytoplasmic multiprotein complexes mediating the
proteolytic activation of caspase-1, which are essential for the
production of biologically active interleukin-1b (IL-1b).
We have reported a mouse model generated by targeted trun-
cation of pyrin, which demonstrated that pyrin plays a role in the
regulation of the inflammasome, mediated through PYRIN
domain interactions (Chae et al., 2003). Nevertheless, the pyrin
truncation mice did not show an overt phenotype related to
FMF, suggesting that FMF may be caused by a gain of function
induced by disease-associated missense changes in pyrin.
Indeed, no null FMF mutations have been identified to date.
Most FMF-associated mutations are clustered in the C-terminal
B30.2 domain of pyrin, and therefore this domain has been the
focus of current thinking on the pathogenesis of FMF. The
B30.2 domain has a role in attenuating the activation of IL-1b
through direct interaction with caspase-1 as well as other inflam-
masome components, such as the NACHT, LRR, and pyrinImmunity 34, 755–768, May 27, 2011 ª2011 Elsevier Inc. 755
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et al., 2006; Papin et al., 2007). Possibly because of technical
differences, transfection studies have yielded contradictory
results regarding the roles of wild-type and mutant pyrin in IL-1
activation and inflammation more broadly (Chae et al., 2006,
2008; Papin et al., 2007; Yu et al., 2006, 2007).
In order to study the pathogenesis of FMF induced by muta-
tions in the B30.2 domain in vivo, we have generated various
gene insertion ‘‘knockin’’ (KI) mouse models with three frequent
FMF-associated B30.2 mutations (M680I, M694V, and V726A)
by inserting the B30.2 domain of human pyrin into mouse pyrin,
which lacks a B30.2 orthologous domain. In contrast with the
aforementioned truncation model, the KI mice showed severe
spontaneous inflammatory phenotypes comparable to the
inflammation of FMF patients. With these KI mice, we explored
the pathogenesis of FMF not only at the physiological level but
also at the molecular level and found that the inflammatory
phenotype of these mice is mediated by the ASC-dependent,
NLRP3-independent production of IL-1b by bone marrow-
derived cells.
RESULTS
Insertion of FMF-Associated Mutant B30.2 Domains
Induces Inflammation in Mice
Although exon 10 of mouse Mefv has substantial homologies at
the nucleotide level with exon 10 of human MEFV, which
encodes the B30.2 domain, the mouse pyrin protein does not
have the B30.2 domain because of frame-shift variations (Chae
et al., 2000). Thus, to insert FMF-associated B30.2 mutations
into mouse pyrin, exons 7–10 of mouse Mefv were replaced
with exons 7–10 of human MEFV encoding wild-type (WT) or
FMF-associated mutant B30.2 domains. The resultant fusion
proteins were expected to express WT or one of three mutant
human B30.2 domains (M680I, M694V, or V726A) (Figure 1A;
Figures S1A and S1B available online). Heterozygotes of all
mutant KI mice (MefvM680I/+, MefvM694V/+, and MefvV726A/+)
were born from chimeric males and appeared normal without
evidence of pathology. However, heterozygous WT B30.2
domain KI mice (MefvB30.2/+) were not born. A total of 44 chimeric
WT B30.2 males were produced from five different positive
embryonic stem (ES) cell clones, which had been screened by
Southern blot and confirmed by long-range PCR. In spite of
high amounts of coat color chimerism, none of the chimeric
males produced heterozygotes. Homozygous mutant KI mice
(MefvM680I/M680I, MefvM694V/M694V, and MefvV726A/V726A) were
born from interbred heterozygotes in Mendelian ratios.
All homozygous mutant KI mice spontaneously developed
inflammatory phenotypes, withMefvV726A/V726A the most severe.
MefvV726A/V726A pupswere runted with scales on the skin as early
as 1week of age. SomeMefvV726A/V726A pupsdied aroundweek2
to 3, and their growth was severely retarded (Figure 1B; Fig-
ure S1C). Gross and histological examination of MefvV726A/V726A
mice revealed severe spontaneous inflammation in multiple
tissues such as skin, liver, joints, and bone marrow (BM) (Fig-
ure 1C). As in human FMF, a substantial infiltration of leukocytes,
mainly neutrophils and macrophages, was also observed in all
inflamed tissues. Moreover, homozygous KI mice showed
anemia, lymphopenia, and granulocytosis in the peripheral blood756 Immunity 34, 755–768, May 27, 2011 ª2011 Elsevier Inc.(Table S1). Although MefvM680I/M680I and MefvM694V/M694V mice
could not be distinguished from their WT or heterozygous
littermates for several weeks after birth, milder but detectable
illness developed after 4 to 8 weeks of age for MefvM680I/M680I
mice (Figure 1D) and after more than 20 weeks after birth
for MefvM694V/M694V mice, with growth retardation, wasting,
dermatitis, and arthritis, though less severe than that seen with
homozygous MefvV726A/V726A mice. Thus, the insertion of
FMF-associated mutant B30.2 domains into mouse pyrin
induces spontaneous inflammation that is similar to or more
severe than the inflammation observed in FMFpatients. Severity,
as assessed by the age of onset, varies inversely with the severity
of human phenotypes (MefvV726A/V726A > MefvM680I/M680I >
MefvM694V/M694V).
The KI Mice Have Increased CD11b+ Cells
in Lymph Node, Spleen, and Blood
The homozygous KI mice also showed lymphadenopathy and
splenomegaly (Figure S1D). Histological examination of spleens
from MefvV726A/V726A mice revealed the loss of normal germinal
center architecture and the infiltration of inflammatory cells (Fig-
ure 1E). Indeed, flow cytometric analysis ofMefvV726A/V726A sple-
nocytes revealed that CD11b+ cells were markedly expanded
whereas T and B cells were substantially decreased (Figure 2A).
The expansion in numbers of CD11b+ cells was also observed in
lymph node (LN) (Figure S2A), BM, and peripheral blood as early
as 4 weeks and increasing with age. Subsequent analysis
showed that the vast majority of the increased CD11b+ cells
were Ly-6G+ neutrophils (granulocytes) (Figure 2A; Figure S2A),
and the absolute number of F4/80+ cells (monocytes or macro-
phages) was also increased. In MefvM680I/M680I (Figure S2B)
and MefvM694V/M694V (data not shown) mice, the numbers of
CD11b+ cells were also substantially increased, although not
to the degree seen in MefvV726A/V726A mice.
The Inflammation of KI Mice Is Induced by a Gain
of Function in the Mutant B30.2 Domain
with Dosage Effect
Because, in the homozygous KI mice, the disease was induced
by the modified pyrin with insertion (KI) of the FMF-associated
mutant B30.2 domain rather than disruption of WT pyrin, we
hypothesized that FMF-associated pyrin mutations might lead
to a gain of function. However, heterozygotes showed normal
growth without any inflammatory symptoms whereas homozy-
gous KI mice were diseased, which is consistent with the reces-
sive mode of inheritance for FMF and a loss-of-function model.
To help clarify this issue, pyrin-null (Mefv/) mice were gener-
ated (Figure S1E) and crossed withMefvV726A/+ mice to produce
hemizygotes (MefvV726A/) that expressed only mutant pyrin
from a single allele. Mefv/ mice were grossly normal, and
MefvV726A/ mice also showed normal features of growth and
no signs of disease (Figures 2B and 2C). These data indicate
that missense mutations on both alleles are necessary for the
induction of inflammation in KI mice, implying the importance
of the amount of mutant pyrin in inducing the inflammation.
Indeed, in macrophages, the LPS- and IL-4-induced expression
of pyrin from both alleles (Mefv+/+) was about two times the pyrin
expression from only a single allele (Mefv+/) (Figure 2D, right),
and the expression of mutant pyrin in homozygotes was
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Figure 1. Pyrin with an FMF-Associated Mutant B30.2 Domain Induces Inflammation in Mice
(A) Comparison of the schematic structure of pyrin proteins of human, mouse, and KI mice in which mouse pyrin is fused with the human B30.2 domains.
(B and D) Growth curves for (B) V726A mutant KI males (WT, n = 5; heterozygotes, n = 9; homozygotes, n = 4) and (D) M680I mutant KI females (WT, n = 9;
heterozygotes, n = 10; homozygotes, n = 6). Data are as means ± SD.
(C) Hematoxylin and eosin (H&E)-stained ear sections (2003) and liver sections (2003) from 8-week-old WT andMefvV726A/V726A mice, and H&E-stained section
(1003) (bottom) of ankle joints of 4-week-old MefvV726A/V726A mice.
(E) H&E-stained spleen sections (403) from 8-week-old WT and MefvV726A/V726A mice.
Additional information is provided in Figure S1 and Table S1.
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Molecular Pathogenesis of FMFsubstantially higher than heterozygotes both before (Figure 2D,
left) and after (Figure 2D, middle) stimulation of mouse pyrin
expression with LPS and IL-4. Taken together, these results
suggest that this mouse model of FMF can be explained by the
gain-of-function and gene-dosage effect of mutant pyrin.BM-Derived Cells Are Necessary and Sufficient
for the Induction of FMF Inflammation
Because pyrin is expressed primarily in myeloid cells, and KI
mice showed the expansion in numbers of CD11b+ cells in
LNs, spleen, and blood, we hypothesized that BM-derived cellsImmunity 34, 755–768, May 27, 2011 ª2011 Elsevier Inc. 757
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Molecular Pathogenesis of FMFmight be critical for the pathogenesis of KI mice. When BM cells
from MefvM680I/M680I mice were transferred to lethally irradiated
WT mice, the recipient mice started losing body weight and
developed dermatitis with spontaneous infiltration of inflamma-
tory cells, whereas the control mice that had received WT BM
cells showed normal growth without an inflammatory phenotype
(Figures 3A and 3B). Moreover, the expansion in numbers of the
CD11b+myeloid cellswas also observed in the blood (Figure 3C),
LNs, and spleen of the recipient mice as seen in unmanipulated
MefvM680I/M680I mice, indicating that BM cells of KI mice trans-
ferred the KI phenotype intoWTmice. Conversely, we also trans-
ferred congenic CD45.1 WT BM cells to CD45.2MefvV726A/V726A
mice suffering from severe inflammation. Most of the recipients
showed normalized numbers of CD11b+ cells with gradual
body weight gain to the normal body weight range of WT adult
mice (Figures 3D and 3E). In contrast, we also observed that
a few recipients failed to gain bodyweight and still had expanded
CD11b+ cells in their blood. Subsequent cytometric analyses
showed that the rescued mice were well reconstituted with WT
donor cells as expected, but therewas no reconstitution of donor
cells in the sick recipients (Figure 3F). Because of a tendency of
early death and small body size, we had given WT BM cells to 3-
week-old MefvV726A/V726A mice intraperitoneally rather than by
intravenous injection and had irradiated the recipients with two
doses of 3.5 Gy. As evidenced by the flow cytometric data,
this regimen did not result in complete chimerism in all recipi-
ents. However, the data indicate a strong correlation between
establishment of chimerism and phenotypic rescue.
The Expansion of Myeloid Cell Numbers Is Induced
by Soluble Factors
Next we investigated whether the expansion of CD11b+ cell
numbers in KI mice was due to the direct involvement of the
FMF-associated mutant B30.2 domain in the proliferation of the
inflammatory cells or initiated by soluble factors secreted from
thecells expressingmutant pyrin.WeusedmixedBMtransplants
in which CD45.1+ WT BM cells were premixed with CD45.2+
MefvM680I/M680I or CD45.2+ WT BM cells and transferred into
lethally irradiated CD45.1+CD45.2+ heterozygous WT recipients.
We observed that within both recipients of CD45.1+WT-CD45.2+
WT BM cells and of CD45.1+ WT-CD45.2+MefvM680I/M680I BM
cells, each donor accounted for between 40% and 50% of total
blood cells at 6 weeks after BM transplant. Subsequent analysis
of blood cell lineages differentiated from each donor showed that
CD11b+ cells comprised more than 50% of both CD45.1+ and
CD45.2+ cells in the recipients of mixed CD45.1+ WT-CD45.2+
MefvM680I/M680I BM cells, whereas CD11b+ cells comprised only
about 20% of each lineage in mixed WT chimeras (Figure 3G).
These data suggest that the expansion of myeloid cell numbersFigure 2. Expansion of CD11b+ Cells and Gain-of-Function B30.2 Muta
(A) Flow cytometry analyses of spleens from 4- and 12-week-oldMefvV726A/V726A
(CD3 and CD19 for T cells and B cells, respectively, first row) andmyeloid (CD11b,
F4/80+ monocytes or macrophages were analyzed (third row). Numbers indicat
sentative of three independent experiments.
(B) Generation of hemizygous (MefvV726A/) KI mice for the mutant B30.2 domain
offspring. Data are representative of three independent experiments.
(C) Body weights of six 8-week-old males of Mefv+/+, MefvV726A/+, MefvV726A/V726
(D) Expression of pyrin in peritoneal macrophages from M680I-KI and pyrin-defic
Additional information is provided in Figure S2.is mediated by soluble factors, such as cytokines, abnormally
secreted from mutant cells rather than a direct effect of mutant
pyrin in the cells expressing it.
The Disease of KI Mice Is Induced by IL-1b
In order to find the soluble factors that mediate inflammation in
the KI mice, various cytokines were measured from the sera of
MefvV726A/V726A mice. We observed a significant elevation of
multiple cytokines, chemokines, and hematopoietic factors in
the sera ofMefvV726A/V726A mice compared to the WT or hetero-
zygous littermates (Figure 4A; Figure S3A). Of the elevated
cytokines, we primarily focused on IL-1b because it has been
demonstrated that pyrinhasa role in the regulation of IL-1b secre-
tion (Chae et al., 2003, 2006, 2008; Papin et al., 2007; Yu et al.,
2006). The functionally active 17 kDa IL-1b is secreted mainly
from innate immune cells after proteolytic cleavage of 34 kDa
pro-IL-1b by activated caspase-1. For the activation of cas-
pase-1, the 45 kDa pro-caspase-1 must be cleaved into 22 and
10 kDa catalytic subunits (p20 and p10, respectively). Therefore,
the activation and secretion of both IL-1b and caspase-1 was
examined by immunoblot from the cell culture supernatants of
the BM CD11b+ cells and BM-derived macrophages (BMDMs).
WT andMefvV726A/+ cells secreted IL-1b and p10 only after stim-
ulation with LPS followed by ATP treatment, whereas the cells
stimulated with LPS alone did not secrete IL-1b and p10 despite
high pro-IL-1b expression. In contrast, IL-1b and p10 were highly
secreted from BM CD11b+ cells and BMDMs of MefvV726A/V726A
mice by LPS stimulation alone without ATP treatment (Figure 4B;
Figure S3B). Moreover, we could also observe the secretion of
p10 from the untreated MefvV726A/V726A BM CD11b+ cells, indi-
cating that the inflammasome is constitutively activated in the
myeloid cells of homozygous KI mice.
To further investigate the role of IL-1b in the pathogenesis of KI
mice in vivo, we crossedMefvV726A/V726Amicewith IL-1 receptor-
deficient (Il1r1/) mice to generate MefvV726A/V726AIl1r1/
mice. The MefvV726A/V726AIl1r1/ mice were grossly normal
without any inflammatory phenotypes such as myeloid cell
number expansion (Figures 4C and 4D). However, the inflamma-
some of the BM CD11b+ cells was still activated and IL-1b was
secreted from the cells with LPS alone (Figure 4E), suggesting
that constitutive inflammasome activation may be a primary
event in FMF KI mice. Taken together, these results demonstrate
that IL-1b is a key soluble factor for inducing the inflammation in
these mice and that IL-1b blockade ameliorates the disease.
The Inflammasome Is Highly Activated
in the Macrophages of FMF Patients
Consistent with several case reports demonstrating the marked
amelioration of symptoms in FMF patients upon treatment withtions with a Gene Dosage Effect
mice. Total splenocytes were analyzed for the relative frequencies of lymphoid
second row) cells. Within CD11b+-gatedmyeloid cells, Ly-6G+ neutrophils and
e percentage of total cells in respective quadrants or gates. Data are repre-
. Peripheral blood cells were analyzed for CD11b+ cells from their 8-week-old
A, MefvV726A/, and Mefv/.
ient mice after 24 hr of culture.
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Molecular Pathogenesis of FMFrecombinant IL-1 receptor antagonist (Belkhir et al., 2007;
Bilginer et al., 2009; Calligaris et al., 2008; Chae et al., 2006; Kuijk
et al., 2007;Moser et al., 2009; Roldan et al., 2008), the aforemen-
tioned mouse data suggest that the inflammatory symptoms of
human FMF may also be triggered by IL-1b. However, there
has been no direct evidence showing the constitutive activation
of the inflammasome and subsequent high IL-1b production
frommyeloid cells of FMF patients. Therefore, we first examined
IL-1b secretion from peripheral blood mononuclear cells
(PBMCs) of FMFpatientswho hadmutations in theB30.2 domain
of pyrin. Similar to the FMF KI mice, we could observe that,
without ATP treatment, various Toll-like receptor (TLR) ligands
could induce IL-1b secretion from PBMCs of most of the FMF
patients tested (FiguresS4A–S4C). However, someof the healthy
controls also secreted IL-1b in response to LPS alone. Moreover,
PBMCs from a few FMF patients secreted less IL-1b than
a healthy control, though most FMF patients secreted higher
amounts of IL-1b than healthy controls (Figure S4D). This incon-
sistency may be due to differences in pyrin expression that may
in turn result from genetic or environmental factors, including
treatment (Booty et al., 2009; Chae et al., 2008).
In order to minimize the variation coming from treatments and
environmental factors, the PBMCs were first differentiated into
macrophages in vitro, and IL-1b secretion was then measured
(Figures 5A and 5B). In these experimental conditions, marked
IL-1b and p20 secretion were observed in FMF patients but not
healthy controls when the macrophages were stimulated with
LPS followed by ATP treatment, whereas they were not secreted
or secreted at low amounts by LPS alone. We also examined
inflammasome activation from the macrophages in which pyrin
expression was highly induced by IFN-g treatment for 16 hr prior
to LPS stimulation. The increased expression of pyrin was veri-
fied in the IFN-g-treated macrophages from both patients and
healthy controls, but, similar to the inflammasome activation in
the FMFKImice, IL-1b and p20were secreted only frompatients’
macrophages by LPS stimulation alone without ATP treatment.
These results suggest that mutant pyrin is involved in inflamma-
some activation to a much greater degree than WT pyrin.
The Adaptive Immune System Has No Major Role
in the KI Phenotype
Figures 2 and 3 indicate that the inflammatory phenotype of KI
mice is initiated by hematopoietic stem cells and that themyeloidFigure 3. The Inflammatory Phenotypes of KI Mice Are Induced from C
(A–C) BM cells from KI mice induce inflammatory phenotypes in WT mice. WT mi
mice intravenously.
(A) Body weight after bone marrow transplantation (BMT). Data are shown in per
from four of each recipient.
(B) H&E-stained ear sections (1003) from both recipients (WT BM cells into WT
(C) Flow cytometry analyses of peripheral blood cells from both recipients after 1
(D–F) BM cells from congenic CD45.1 WT mice cure the inflammatory phenotype
from either WT or MefvV726A/V726A mice intraperitoneally.
(D) Flow cytometry analyses of peripheral blood cells after 10 weeks of BMT.
(E) Body weight after BMT. Data are shown in percent relative body weight chan
(F) The degree of chimerism measured concomitantly by staining the congenic m
(G) The expansion of CD11b+ cell numbers is mediated by soluble factors. Conge
or CD45.2+ MefvM680I/M680I BM cells (bottom) and injected into lethally irradiated
after 6 weeks of BMT for the chimerism (dot plot) and relative CD11b+, CD3+, and C
representative of three independent experiments.lineage is probably critical for thepathogenesis of FMF.However,
in KI mice, we could also observe an increased fraction of acti-
vated memory T cells (Figure S5), though the overall numbers
of lymphocytes were relatively low in the LN and spleen of homo-
zygous KI mice. Moreover, the cytokines IL-2, IL-9, IL-17, and
IFN-g, which are known to be primarily produced by T cells,
were also significantly increased in the sera of KI mice (Fig-
ure S3A). Therefore, to testwhether T cells have a role in the path-
ogenesis of the KI phenotype, we producedMefvV726A/V726Amice
on the RAG1-deficient background (MefvV726A/V726ARag1/).
MefvV726A/V726ARag1/ mice were runted with inflammatory
phenotypes similar toMefvV726A/V726ARag1+/+ mice and showed
constitutive inflammasome activation in their myeloid cells com-
parable to what was observed in cells from MefvV726A/V726A
Rag1+/+ mice (Figures 6A–6D). Nevertheless, activated T cells
may still amplify the knockin phenotype, because several cyto-
kines were significantly decreased in MefvV726A/V726ARag1/
mice as compared to MefvV726A/V726ARag1+/+ mice, though the
amounts were still higher than in WT mice (Figure S3).
Inflammation in FMF KI Mice Is ASC Dependent
but NLRP3 Independent
Finally, we investigated the underlyingmechanism for the inflam-
masome activation of the FMF KI mice in vivo. Because
apoptosis-associated speck-like protein with a CARD (ASC) is
the essential adaptor molecule among the components of
most inflammasomes, and pyrin itself can interact with ASC
through cognate PYRIN domain interactions, we crossed our
MefvV726A/V726A mice with ASC-deficient mice (Asc/).
MefvV726A/V726AAsc/ mice showed normal growth without
any inflammatory phenotype or myeloid cell expansion (Figures
7A and 7B). We could also observe the complete ablation of
IL-1b secretion and caspase-1 activation from the BM CD11b+
cells of MefvV726A/V726AAsc/ mice after LPS stimulation, even
with ATP treatment, as seen with the cells from Asc/ mice
(Figure 7C), indicating that ASC is critical for the caspase-1
activation mediated by FMF-associated pyrin mutations.
Given the association of ASCwith NLRP3 in the NLRP3 inflam-
masome, we asked whether the deficiency of NLRP3 would
affect the FMF KI phenotype. As a control, we observed that
the CD11b+ cells from NLRP3-deficient (Nlrp3/) mice did not
secrete IL-1b in response to the LPS and ATP stimulation
in vitro (Figure 7D). However, the NLRP3-deficient KI miceells of the Hematopoietic Lineage
ce were lethally irradiated and given BM cells from eitherMefvM680I/M680I or WT
cent relative body weight changes as means ± SD of duplicate measurements
and MefvM680I/M680I BM cells into WT) after 6 weeks of BMT.
8 weeks of BMT. Data are representative of three independent experiments.
s of CD45.2 KI mice. MefvV726A/V726A mice were irradiated and given BM cells
ges of individual recipients as indicated.
arker of donor cells (CD45.1).
nic CD45.1+ WT BM cells were premixed with either CD45.2+ WT BM cells (top)
CD45.1+ and CD45.2+ WT mice. Flow cytometry analyses of peripheral blood
D19+ cells according to the origin of each cell population (histogram). Data are
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Figure 4. Inflammation in KI Mice Is Induced by IL-1b
(A) Luminex analysis of serum cytokines of 8-week-old Mefv+/+Rag1+/+, MefvV726A/+Rag1+/+, MefvV726A/V726ARag1+/+, Mefv+/+Rag1/, and MefvV726A/V726A
Rag1/ mice. *p < 0.05; **p < 0.0001; ***p < 0.000001.
(B) CD11b+ cells fromBMofWT,MefvV726A/+, andMefvV726A/V726Amicewere stimulatedwith LPS or no stimulus for 3 hr followed by treatment with or without ATP.
Cell culture supernatants (Sup.) and cell lysates (Lys.) were analyzed by immunoblotting.
(C–E) Analyses of MefvV726A/V726A mice on the Il1r1/ background.
(C) Body weights of 8-week-old males.
(D) Flow cytometry analyses of peripheral blood cells from 8-week-old mice. Data are representative of three independent experiments.
(E) Inflammasome activation in MefvV726A/V726A mice with Il1r1/ background. Culture supernatants and lysates from BM CD11b+ cells were collected and
subjected to immunoblot as described in (B).
Additional information is provided in Figure S3.
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Figure 5. Inflammasome Activation in FMF
Patients
Macrophages differentiated from PBMCs of (A)
two healthy donors (controls 8 and 9), two FMF
patients (FMF 9, homozygote of M694V; FMF 10,
compound heterozygote of V726A/E148Q), (B) two
healthy donors (controls 10 and 11), and two FMF
patients (FMF 11, heterozygote of V726A; FMF 12,
compound heterozygote of V726A/P369S) were
treated with IFN-g or no stimulus for 16 hr.
Macrophages were treated as described in Fig-
ure 4B, andcell culture supernatants (Sup.) andcell
lysates (Lys.) were analyzed by immunoblotting.
Additional information is provided in Figure S4.
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Molecular Pathogenesis of FMF(MefvV726A/V726ANlrp3/) were runted and showed similar in-
flammatory phenotypes to the symptoms of KI mice expressing
Nlrp3 (MefvV726A/V726ANlrp3+/+) (Figures 7B and 7E). Moreover
we observed that the LPS-stimulated CD11b+ cells of
MefvV726A/V726ANlrp3/ actively secreted IL-1b and p10, even
without ATP treatment, whereas the cells of Mefv+/+Nlrp3/
did not secrete IL-1b after LPS stimulation with ATP treatment
(Figure 7D). These results demonstrate that NLRP3 is not neces-
sary for the caspase-1 activation of the FMF KI mice.
We also examined other NLRP3-independent inflammasomes
by introducing Salmonella typhimurium or double-stranded DNA
into BMDMs to interrogate NLRC4 (IPAF, ICE protease-acti-
vating factor) or AIM2 (absent in melanoma 2) inflammasome
activation, respectively (Figures S6A–S6C). IL-1b secretion inImmunity 34, 755–these short-term assays was similar
among WT, pyrin-deficient, and FMF KI
mice, which suggests that the NLRC4
and AIM2 inflammasomes do not mark-
edly contribute to caspase-1 activation
of the FMF KI mice. Conversely, data
from pyrin-deficient mice demonstrate
that pyrin is dispensable for NLRC4 and
AIM2 inflammasome activation as well
as NLRP3 activation by LPS and ATP.
Nevertheless, macrophages from pyrin-
deficient mice produced somewhat
higher amounts of mature IL-1b com-
pared with WT mice when stimulated
with LPS alone for 1 to 3 days, as seen
in our previous study of pyrin-truncation
mice (Figure S6D; Chae et al., 2003).
Taken together with previously reported
findings on the direct interaction of pyrin
with ASC, our results provide evidence
for an ASC-dependent, pyrin inflamma-
some, which is activated in the presence
of the FMF-associated mutations of
pyrin.
DISCUSSION
In this manuscript we described the
profound phenotype established by intro-
ducing FMF-associated mutations intothe mouse germline. Consistent with the conception of FMF as
an autoinflammatory disorder, the cells and molecules of the
innate immune system are strongly implicated in the pathogen-
esis of disease in these animals. BM-derived cells are both
necessary and sufficient to confer the phenotype, which includes
a marked expansion of granulocyte numbers in the blood and
peripheral lymphoid organs that persists on a Rag1/ back-
ground. Extending earlier data implicating IL-1b in the pathogen-
esis of FMF, the disease phenotype is markedly attenuated in
mice deficient for the IL-1 receptor, and additional crosses
provided genetic evidence for an ASC-dependent, NLRP3-inde-
pendent pyrin inflammasome.
Characterization of these FMF KI mice provides yet another
step in a paradigm shift in our understanding of the genetics of768, May 27, 2011 ª2011 Elsevier Inc. 763
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Figure 6. Analyses of MefvV726A/V726A Mice on a Rag1–/– Background
(A and B) Flow cytometry analyses of peripheral blood cells (A) and splenocytes (B) from 8-week-old mice analyzed as described in Figure 3C. Data are
representative of three independent experiments.
(C) Body weights of 8-week-old males.
(D) Inflammasome activation in MefvV726A/V726A mice with Rag1/ background. Culture supernatants and lysates from BM CD11b+ cells were analyzed by
immunoblotting.
Additional information is provided in Figure S5.
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Molecular Pathogenesis of FMFFMF. Based on segregation analysis in Sephardi Jewish families
with severe disease (Sohar et al., 1967), FMF has long been
considered an autosomal-recessive illness, and in fact the posi-
tional cloning studies leading to the identification of MEFV were
based on this assumption. However, the availability of genetic
testing has led both to the recognition of a biochemical pheno-
type in asymptomatic heterozygotes (Lachmann et al., 2006)
and to the diagnosis of FMF in patients with relatively mild clinical
phenotypes. As many as 30% of the patients diagnosed with
FMF have only a single demonstrable mutation despite
sequencing of the entireMEFV genomic region and several other764 Immunity 34, 755–768, May 27, 2011 ª2011 Elsevier Inc.known autoinflammatory genes (Booty et al., 2009; Marek-Yagel
et al., 2009; Ozen, 2009). This observation, taken together with
the fact that nearly all FMF-associated mutations are missense
rather than null mutations, has led to a reconsideration of the
simple loss-of-function recessive model of FMF inheritance.
Thedatapresentedhereaddsubstantially to thecase for again-
of-function model. In the current study, we have shown that the
insertion of three different FMF-associated mutant human B30.2
domains into mouse pyrin induced inflammatory phenotypes
similar toormoresevere than thoseseen inFMFpatients,whereas
deletingmousepyrin producednoovert inflammatory phenotype.
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Figure 7. FMF-Associated B30.2 Mutations Activate an ASC-Dependent but NALP3-Independent Pyrin Inflammasome
(A–C) Analyses of the FMF KI (MefvV726A/V726A) mice with Asc/ background.
(A) Flow cytometry analyses of peripheral blood cells from 8-week-old mice analyzed as in Figure 3C. Data are representative of three independent experiments.
(B) Body weights of indicated 8-week-old males.
(C) Inflammasome activation in MefvV726A/V726A mice with Asc/ background. Culture supernatants and lysates from BM CD11b+ cells were analyzed by
immunoblotting.
(D and E) Analyses of the FMF KI (MefvV726A/V726A) mice with Nlrp3/ background.
(D) Inflammasome activation in MefvV726A/V726A mice with Nlrp3/ background. Culture supernatants and lysates from BM CD11b+ cells were analyzed by
immunoblotting.
(E) Flow cytometry analyses of peripheral blood cells from 8-week-old mice analyzed as in Figure 3C. Data are representative of three independent experiments.
Additional information is provided in Figure S6.
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Molecular Pathogenesis of FMFNeither heterozygous nor hemizygous KI mice exhibited the
cardinal features seen in homozygotes, indicating a gene dosage
effect. The fact that pyrin expression is cytokine inducible
suggests a possible feed-forward mechanism in which homozy-
gous KI cells may express more pyrin at baseline, which in turn
leads to inflammatory cytokine production and further increases
in pyrin expression. Such a gene dosage effect may also be oper-
ative in humans, in that higher pyrin protein expression has been
observed in the leukocytes of FMF patients, compared with
healthy controls (Booty et al., 2009; Chae et al., 2008).
It is possible that the disease phenotype observed in FMF KI
mice is due not to the expression of the specific FMF-associatedB30.2 pyrin mutations but rather to the expression of any pyrin
that chimerizes the N-terminal mouse pyrin with the C-terminal
human B30.2 domain. Absent the generation of knockin mice
for the wild-type human B30.2 domain, this will always remain
formally possible. However, against this hypothesis, there is
a genotype-phenotype relationship in the mice, with the severity
of the phenotype in the mice inversely proportionate to the
severity of the phenotype associated with the corresponding
genotype in humans. A similar observation has recently been
reported for NLRP3 KI mice (Brydges et al., 2009). Of possible
relevance in the case of pyrin, mice do not express a C-terminal
B30.2 domain (Chae et al., 2000). Thus, it is not totally surprisingImmunity 34, 755–768, May 27, 2011 ª2011 Elsevier Inc. 765
Immunity
Molecular Pathogenesis of FMFthat mice harboring the wild-type human B30.2 domain may
express a phenotype even more severe (embryonic lethality)
than the V726A homozygous genotype, which is associated
with the mildest FMF phenotype in humans.
We present several lines of evidence that IL-1 plays a crucial
role in the phenotype observed in mice homozygous for FMF-
associated pyrin mutations. To date there are four different
macromolecular inflammasomes, nucleated by NLRP1,
NLRP3, NLRC4, and AIM2. The NLRP3 inflammasome has
been shown to be activated by a wide range of pathogen-asso-
ciated or danger-associated molecular patterns (PAMPs,
DAMPs) and murine Nlrp3/ cells do not produce any detect-
able amount of IL-1b in response to LPS and ATP in vitro (Maria-
thasan et al., 2006; Sutterwala et al., 2006). Nevertheless, we
have found that the NLRP3 inflammasome has no role in the
inflammation of FMF KI mice. In addition, we did not observe
any differences in IL-1b secretion among WT, pyrin-deficient,
and KI macrophages induced by double-stranded DNA or
S. typhimurium, suggesting that the AIM2 or NLRC4 inflamma-
some is not involved in the inflammation of KI mice. The neces-
sity of ASC for the inflammation of KI mice also excludes the
NLRP1 inflammasome from the pathogenesis of FMF inflamma-
tion, because murine NLRP1 orthologs are predicted to be
unable to interact with ASC because of lack of functional PYRIN
domains. Indeed, ASC is dispensable for NLRP1-dependent
caspase-1 activation in mouse macrophages (Hsu et al., 2008).
Taken together, these data suggest a previously unrecognized
ASC-dependent inflammasome in which mutant pyrin induces
IL-1b activation.
An inhibitory role of pyrin in caspase-1 activation has been
proposed in our previous study with a mouse model expressing
a truncated form of pyrin (Chae et al., 2003). However, this inter-
pretation has been debated because the pyrin-truncation mice
express a functional N-terminal PYRIN domain that can interact
with ASC. In the current study, we have shown that pyrin-null
macrophages produced higher amounts of mature IL-1b when
stimulated with LPS alone for 1 to 3 days, although they did
not show evidence of increased IL-1b activation in short-term
assays of inflammasome activation. Moreover, neither pyrin-
truncation nor -deficient mice exhibit a spontaneous inflamma-
tory phenotype. These results suggest a more subtle inhibitory
role of pyrin that may be limited to noninflammasome-mediated
IL-1b activation.
To test the hypothesis that pyrin mutations cause IL-1b activa-
tion in FMF patients, we cultured patient or control PBMCs for
7 days to minimize the effect of the patients’ colchicine treat-
ment, and then induced pyrin with IFN-g (Centola et al., 2000).
In 4/4 FMF patients, but 0/4 controls, we observed caspase-1
activation and IL-1b secretion even without an ATP second
signal. These data provide a scientific basis for IL-1 inhibition
in the treatment of FMF, particularly in patients with life-threat-
ening amyloid deposition.
Our data also establish a conceptual basis for the possible
development of hematopoietic stem cell therapy for refractory
FMF. In reciprocal BM transfer experiments, we found that cells
of the hematopoietic lineage are both necessary and sufficient
for the FMF KI phenotype. In a patient with FMF who underwent
bone marrow transplantation for congenital dyserythropoietic
anemia, FMF symptoms completely resolved off colchicine treat-766 Immunity 34, 755–768, May 27, 2011 ª2011 Elsevier Inc.ment (Milledge et al., 2002). Although the morbidity of allogeneic
bone marrow transplantation generally makes this an unattrac-
tive alternative, the possibility of gene correction with inducible
pleuripotent stem cells may eventually modify this calculus.
FMF KI mice may also shed light on the role of pyrin variants in
human history and evolution. The extraordinarily high carrier
frequency of FMF-associatedMEFVmutations in certain popula-
tions, coupled with the fact that different mutations predominate
in geographically proximate ethnic groups, strongly suggests
that heterozygous FMFmutations may confer a selective advan-
tage against some as-yet-unknown pathogen. Moreover,
sequence comparisons of the C-terminal B30.2 doman of pyrin
with nonhuman primates suggest episodic positive selection
(Schaner et al., 2001). The fact that several disease-associated
mutations are clustered around a putative binding pocket in
the C-terminal B30.2 domain provides a possible structural basis
for this hypothesis (Masters et al., 2009). It is thus possible that
one of the functions of pyrin is to serve as an intracellular
receptor for one or more PAMPs. FMF KI mice may serve as
the experimental platform to test such hypotheses, thereby al-
lowing us to probe these most fundamental questions regarding
the role of pyrin and its mutants in human health and disease.
EXPERIMENTAL PROCEDURES
Mice
Generation of FMF KI Mice
With pPNT-double loxP as a construct backbone, we generated the targeting
constructs by inserting a 6.0 kb KpnI/PvuII genomic fragment encompassing
the end of exon 2 to exon 6 (50 arm) and a 2.5 kb PstI/SpeI genomic fragment
(30 arm) (Figure S1A). For the KI of WT human B30.2 domain, a 1.7 kb genomic
fragment of human MEFV encompassing exons 7 to 10 was inserted
upstream of the 30 arm. The mutant genomic fragments with M680I, M694V,
or V726A were also generated by site-directed mutagenesis with Quick-
Change XL site-directed mutagenesis kit (Stratagene) and inserted in the
upstream segment of the 30 arm. Linearized constructs were introduced into
129/SvEvTac-derived TC-1 embryonic stem (ES) cells. G418- and gancyclo-
vir-resistant clones were screened for homologous recombination by long-
range PCR and Southern blotting (Figure S1B). Heterozygotes generated
from chimeras were crossed with EIIa-Cre transgenic mice (Jackson Labora-
tory) to remove the neo cassette and backcrossed with C57BL/6 mice at least
six generations.
Generation of Pyrin-Deficient Mice
As shown in Figure S1E, the targeting constructs were generated by inserting
a 4.7 kb genomic fragment upstream of exon 1 (50 arm) and a 6.0 kb genomic
fragment encompassing exon 3 to exon 7 (30 arm). By using the linearized
construct, we generated pyrin KO mice as described in the generation of KI
mice and backcrossed them with C57BL/6 mice at least six generations.
Other Mouse Strains
Il1r1/ and Rag1/ mice were from the Jackson Laboratory. Asc/ and
Nlrp3/ mice were a gift from V.M. Dixit (Genentech).
All animal studies were performed according to National Institutes of Health
guidelines and were approved by the Institutional Animal Care and Use
Committee of National Institute of Arthritis and Musculoskeletal and Skin
Diseases (NIAMS).
Flow Cytometry Analysis
RBC-lysed single-cell suspensions were obtained from LNs, spleen, BM, and
peripheral blood and stained with fluorochrome-conjugated antibodies in
PharMingen Stain Buffer (BSA) (BD PharMingen, San Diego, CA). CD3 APC,
CD19 FITC, CD11b PE, Ly-6G FITC, CD3 PerCP-Cy5.5, CD4 FITC, CD8a
APC, CD25 PE, CD44 PE, CD62L PE, and CD69 PE were purchased from
BDPharMingen. F4/80 Alexa647 Abwas purchased from Invitrogen (Carlsbad,
CA). CD45.1 (Alexa488, Alexa647) and CD45.2 (Alexa488, Alexa647) Abs were
Immunity
Molecular Pathogenesis of FMFpurchased from Biolegend (San Diego, CA). Cells were analyzed on a
FACSCaliber flow cytometer (BD Biosciences, San Jose, CA) and analyzed
with FlowJo software (Three Star, Ashland, OR).
Cell Culture and Immunoblots
Peritoneal macrophages were obtained by washing the peritoneum with RPMI
medium. Mouse CD11b+ cells were isolated fromBMwith CD11bMicroBeads
(Miltenyi Biotech, Auburn, CA). BMDMs were obtained by differentiating BM
cells with 10 ng/ml of M-CSF (Peprotech, Rocky Hill, NJ) for 7 days. Peritoneal
macrophages were treated with 1 mg/ml of LPS (Invivogen, San Diego, CA),
12.5 ng/ml of IL-4 (Peprotech), or LPS/IL-4. After 24 hr, cell lysates were
collected. CD11b+ cells or BMDMs were stimulated with LPS (1 mg/ml) or no
stimulus for 3 hr. Cell culture media were changed with fresh media containing
5 mM ATP or media only. After 30 min, cell culture supernatants and cell
lysates were collected.
Blood specimens from healthy controls and FMF patients were drawn after
obtaining informed consent under a protocol approved by the NIAMS Institu-
tional Review Board. PBMCs were isolated by Ficoll-Hypaque centrifugation
and also differentiated intomacrophages with 800 units/ml of GM-CSF (Pepro-
tech). Macrophages were treated with 20 ng/ml of IFN-g (Peprotech) or no
stimulus for 16 hr. Macrophages or PBMCs were stimulated with TLR ligands,
LPS (1 mg/ml), Pam3CSK4 (1 mg/ml), or Gardiquimod (1 mg/ml) (Invivogen). After
3 hr, cell culture media were changed with fresh media, cells were incubated
for 30 min, and cell culture supernatants and cell lysates were collected. Cell
lysates or cell culture supernatants were subjected to SDS-PAGE for immuno-
blot analysis by primary antibodies: anti-mouse pyrin Ab (Chae et al., 2003);
anti-human pyrin Ab (Chae et al., 2006); anti-human IL-1b and mouse IL-1b
Abs (R&D Systems, Minneapolis, MN); anti-mouse caspase-1, human
caspase-1, and actin Abs (Santa Cruz Biotechnology, Santa Cruz, CA).
BMT
For routine BMT experiments, 6- to 8-week-old female mice were lethally
(10 Gy) irradiated the day before BMT and reconstituted by intravenous injec-
tion of 2 3 106 (WT) or 5 3 106 (KI) RBC-lysed BM cells, unless otherwise
specified. For the transfer of KI phenotypes into WT recipients, CD45.1+/+
C57BL/6 mice were used as recipients. For the rescue of inflammatory pheno-
types of KI mice withWT BM cells, 103 106 BM cells from CD45.1+/+ C57BL/6
mice were transferred intraperitoneally into 3- to 4-week-old CD45.2+/+
MefvV726A/V726A mice that had been irradiated with two 3.5 Gy (2 hr interval,
finished 2 hr before i.p. injection). For the mixed BMT, 2 3 106 CD45.1+/+
WT BM cells were premixed with either 2 3 106 CD45.2+/+ WT or 5 3 106
CD45.2+/+ KI (MefvM680I/M680I) BM cells immediately before injection and trans-
ferred to recipients heterozygous for both CD45.1 and CD45.2 antigens.
Measurement of Cytokines, Chemokines,
and Hematopoietic Factors
Sera were obtained from 8-week-old mice and analyzed by Bio-Plex Mouse
Cytokine 23-plex Assay (Bio-Rad, Hercules, CA) according to the manufac-
turer’s instructions.
Statistical Analyses
Statistical analyses were performed with the Student’s t test.
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